Magnolia Medical Technologies develops, manufactures and markets innovative blood collection devices that significantly improve the accuracy, consistency and predictability of critical laboratory tests.The company’s flagship commercial product, Steripath®, is the only FDA-cleared device indicated to reduce blood culture contamination which causes false positive sepsis test results. Steripath has been evaluated exhaustively in clinical studies and demonstrated sustained reductions in contamination of up to 92% with resulting false positive rates as low as 0.2%.Clinically adopted by over 400 hospitals nationwide, including leading academic institutions and IDNs, Steripath has successfully reduced the risk of false positive results for millions of patient sepsis tests.Magnolia has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’s intellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending.For more information, visit www.magnolia-medical.com.

Company Overview: FluoroFinder is developing innovative cloud-based research tools for the search of fluorescent reagents and the design of medical experiments: accelerating the research initiatives aimed at curing Cancer, HIV, Multiple Sclerosis, in addition to other infectious diseases.Simplifying the complexity of managing the life-cycle of reagent selection, FluoroFinder's technology solutions offers unparalleled support and resources to core facilities and labs. Members receive additional benefits and support to drive efficiencies and resource savings. FluoroFinder's technologies save thousands of days - and millions of dollars - for research institutions every year!

Ares Specialty Healthcare Fund is managed by Ares Management. The fund targets businesses focused on pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare devices and supplies and specialty services sectors.

Cetya Therapeutics, Inc. is a development stage pharmaceutical company developing histone deacetylase inhibitors structurally based on the marine natural product Largazole. The company is currently focused on solid tumor oncology and treatment of sickle cell disease.

Principle of this independent Venture Capital and Consulting Group focused on business strategy development and execution, business turnaround, acquisition/divestiture, executive coaching.• Clients and investments in the following markets:o Healthcare and Drug discovery* Medical Device research and development* Information Technologyo Manufacturing/ Distribution o Medical / Dental Training Institute• Support of multiple Venture Capital and Private Equity groups in due diligence of potential investments and acquisitions.o Conceived and developed business Entrepreneurship module in concert with University of Denver Graduate School personnel.

Phase Holographic Imaging (PHI) develops and markets instrumentation for non-invasive time-lapse imaging. The company's HoloMonitor product line is used for long-term quantitative analysis of living cell cultures, particularly in preclinical research and regenerative medicine.

PharmaJet is a private drug delivery technology company which has developed a family of patented, proprietary needle-free injection technologies, able to deliver injection of liquid medicines into the body.The core technology of Pharmajet provides for fixed dosage delivery of drugs and vaccines to intramuscular, subcutaneous and intradermal depths. The sterile syringe is designed for single use, and has an auto-disable feature, thus addressing the elimination of needles, needle re-use and needle stick injury. PharmaJet has received 510(k) marketing clearance of it's devices from the FDA, with designation as a class II medical device. CE Mark and WHO Prequalification . The Pharmajet Needle-Free Injector is Safe, Easy to use, Cost-effective and Comfortable.

Book Trust provides books for kids from low-income families—books that they choose themselves and that become their very own.Studies prove that book choice and ownership inspires a child’s passion for reading and contributes to developing strong literacy skills and becoming life-long learners.Since 2001, Book Trust has: Grown from serving 170 students in Colorado to 53000 children in 19 states Helped children choose and own 2.6 million books Invested $6.5 million in books for children in need Helped teachers earn 37 million bonus points from Scholastic Reading Club which they can use to purchase additional books and classroom resources

Micro-Imaging Solutions, LLC (“MIS”), is located in Denver, Colorado, has patented micro-digital complimentary metal oxide semiconductor (CMOS) imaging technology that will solve important unmet needs in medical endoscopy, the means by which many minimally invasive procedures are conducted. An endoscope is a medical device used to visualize internal organ surfaces, including joints, airways/lungs, urinary and reproductive tracts, and the gastrointestinal tract, among others.The patented technology allows for the miniaturization of digital cameras that are significantly less expensive to produce, have consistently-higher resolution and enable a product design flexibility that does not exist today (disposable). The Company has over 30 issued patents (USA, EU, Japan, Canada), and has additional pending patent applications.

BiOptix Inc has developed a highly-sensitive biosensor for detection of trace amounts (~pg/mm2) of bacteria, viruses, proteins, nucleic acids, antibodies and other biological and chemical agents in real-time and with minimal human intervention.Recently, BiOptix scientists used the prototype biosensor to detect clinically significant levels of human micro RNAs in experimental samples, opening an avenue for early and robust diagnostics of a variety of cancers.The unique patented biosensor design relies upon the common path interferometric detection principle in combination with non-resonant surface plasmon excitation.This design was conceived by BiOptix Chief Scientific Adviser, Dr. John Hall, 2005 Physics Nobel Prize Laureate.Business was sold in 2016

IntelliTec Medical Institute is an institute of higher education in Colorado Springs dedicated to providing excellent healthcare training.We believe the key to building a successful healthcare school is providing you the opportunity to learn and fine-tune your skills in classrooms built just like working laboratories. Here you can develop your medical career under the guidance of expert in-the-field professional instructors. IntelliTec Medical Institute in Colorado Springs is accredited through the Accrediting Bureau of Health Education Schools.IMI was sold to IBMC of Fort Collins in 2015

The HeliScope™ Single Molecule Sequencer is the first genetic analyzer to harness the power of direct DNA measurement, enabled by Helicos True Single Molecule Sequencing (tSMS)™ technology. As the world’s first DNA microscope, the HeliScope instrument performs tSMS chemistry and captures images to observe sequencing-by-synthesis reactions for billions of individual DNA molecules in parallel.

The HeliScope™ Single Molecule Sequencer is the first genetic analyzer to harness the power of direct DNA measurement, enabled by Helicos True Single Molecule Sequencing (tSMS)™ technology. As the world’s first DNA microscope, the HeliScope instrument performs tSMS chemistry and captures images to observe sequencing-by-synthesis reactions for billions of individual DNA molecules in parallel.

Responsible for all facets of this $1.3 Billion division of this $10 Billion company. Division consists of 5000+ people operating in 56 locations in over 100 countries worldwide.• Led the management team that integrated 12 operating business units along with 6 additional acquisitions into a cohesive business unit over a 3 year period.• Restructured into 4 global operating groups; Microbiology, Life Sciences, BioProcess Production and Research Chemicals.• Organically grew the division at 2X market growth rates, 28%. All business units grew faster than market growth rates.• Expanded gross margins by 220 basis points, increasing operating income by 58% while expanding R&D and go to market activities.• Key participant in the merger of Fisher Scientific and Thermo Electron.

Responsible for Worldwide Sales, Marketing, Operations and Engineering & Development for this $700M division of this $1 billion company. Division consists of 6500+ people operating in over 100 countries.• Significant member of team, orchestrating the sale of the KRONE Group to ADC at 4x value identified 18 months earlier.• Delivered 11% increase in revenue and 57% increase in profitability from 2003 to 2004 during sale and transition.• Personally drove key integration teams to identify and achieve synergy benefits.• Traveled extensively throughout ADC / KRONE global footprint to achieve quick understanding of issues and opportunities.Profit and loss responsibility for this $350 million unit of the $1 billion GenTek Corporation. Responsible for all facets of this business, operating in 140 countries with 2500 employees under 26 legal entities throughout the globe. 75% of the revenue came from outside North America.• Successfully navigated the business through the collapse of the telecom market in 2001/02 and Chapter 11 of corporate parent. From 2001 to 2004 :• Revenues +36.7%• Gross Margin +34.7%• OI% (2.5%) to 11.7%• Achieved profitability in every legal entity (26) in the world.• Significant progress made in developing markets in China, India, Russia, Eastern Europe, Middle East.• Accelerated new product activity achieving numerous industry firsts. Examples: AirES, CopperTen, LSA NT, KM8, etc.• Created a lean corporate structure overseeing a global organization with fast communication and decision making.• Maintained all significant employees during the entire industry downturn and Chapter 11.

Profit and Loss responsibility for multiple companies and ventures under the Private Equity Latona Partners Group and the GenTek Corporation. Businesses operated in the Medical, Automotive, Industrial and Telecommunications markets. Responsibilities included Sales, Marketing, Operations, Engineering, Finance and Human Resources.• Developed, in conjunction with senior management team, 5 year strategy to accelerate profitability and cash flow to fund development of telecom business:• Telecom business developed and sold to GenTek Corporation in 1999. Eventually became KRONE Group.• Successfully grew OEM and after market automotive businesses.• Significant leadership position in acquisition and subsequent integration of NOMA – North American based automotive parts company.• Orchestrated dramatic quality and customer satisfaction improvement program, culminating in award as Honda N.A. Top Supplier in 2000. Also achieved QS 9000 and ISO 9000 approvals at all plants.• Established numerous partnerships and ventures across the globe to expand reach without significant investment. Examples: Sumitomo, Thomas & Betts, Phillips Electronics, Sagem, etc.• Member Board of Directors, Craftco, minority owned automotive parts supplier to auto industry.• Member 4 person team from Latona / Lazard consortium. Successfully bid and executed program with Czech Republic Revitalization Agency. Program was to restructure and improve financial health of CR companies. Nine companies participated with over $2 billion in revenues.

Achieved successive promotions in this key division of the GE Corporation. Business grew from approximately $300M in 1977 to a global $3.5 billion business in 1992.• General Manager Engineering & Manufacturing (1990-1992)• Manager Computerized Tomography (1989-1990)• Manager X-Ray Operations (1987-1989)• Plant Manager-Electronics (1986-1987)• Manager, Production & Inventory Planning (1985-1986)• Manager, Operations (1983-1985)• Manager, Quality Programs (1981-1983)• Supervisor, Quality Engineering (1979-1981)• Manufacturing Management Program (1977-1979)